United Therapeutics wants to build a hangar at Concord Municipal Airport for its corporate jet and other aircraft as the company expands its research and development of 3D-printed human organs in ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

United Therapeutics met analysts’ revenue expectations last quarter, reporting revenues of $735.9 million, up 19.7% year on year. It was a slower quarter for the company, ...

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company’s revenue is heavily ...

United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn more on UTHR stock here.

The suit was filed by Sandoz, a division of Novartis. Sandoz has U.S. approval for a generic version of the United Therapeutics drug Remodulin, which costs up to $144,000 a year.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results ...

The hangar will be constructed near an abandoned section of airstrip and vacant landscape on 2.88 acres of land off Regional Drive bordering the town of Pembroke. United Therapeutics expressed ...

Sep. 26—United Therapeutics Corp., a Maryland-based biotechnology company with an artificial organ manufacturing research facility in Manchester's Millyard, has signed a letter of intent to ...

United Therapeutics said the deal expands “existing complementary platform of organ manufacturing programs, which include ex-vivo lung perfusion, xenotransplantation, 3-D bioprinting, and ...

Feb. 28—United Therapeutics wants to build a hangar at Concord Municipal Airport for its corporate jet and other aircraft as the company expands its research and development of 3D-printed human ...

Sep. 26—United Therapeutics Corp., a Maryland-based biotechnology company with an artificial organ manufacturing research facility in Manchester's Millyard, has signed a letter of intent to ...